share_log

Addex Therapeutics | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]

Addex Therapeutics | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]

Addex Therapeutics | 6-K：外国发行人报告
美股SEC公告 ·  2024/07/01 05:09

Moomoo AI 已提取核心信息

Addex Therapeutics announced that shareholders approved all board proposals at its 2024 Annual General Meeting, with 33.79% of outstanding capital represented. Key approvals included the 2023 annual report, financial statements, and compensation report. Board members, including Chairman Dr. Vincent Lawton, were re-elected, and BDO SA was reappointed as auditor.Shareholders also approved amendments to the Articles of Association, including an increase in capital band and conditional share capital. These changes align with revised corporate law and address matters related to shareholders, general meetings, board attributions, and compensation limits. The company's lead drug candidate, ADX71149, recently completed a Phase 2 study for epilepsy treatment.Addex is advancing multiple drug development programs, including dipraglurant for Parkinson's disease-related dyskinesia, and collaborations with Indivior on GABAB PAM for substance use disorder and chronic cough. The company also holds a 20% stake in Neurosterix LLC, which is developing allosteric modulators for various neurological disorders.
Addex Therapeutics announced that shareholders approved all board proposals at its 2024 Annual General Meeting, with 33.79% of outstanding capital represented. Key approvals included the 2023 annual report, financial statements, and compensation report. Board members, including Chairman Dr. Vincent Lawton, were re-elected, and BDO SA was reappointed as auditor.Shareholders also approved amendments to the Articles of Association, including an increase in capital band and conditional share capital. These changes align with revised corporate law and address matters related to shareholders, general meetings, board attributions, and compensation limits. The company's lead drug candidate, ADX71149, recently completed a Phase 2 study for epilepsy treatment.Addex is advancing multiple drug development programs, including dipraglurant for Parkinson's disease-related dyskinesia, and collaborations with Indivior on GABAB PAM for substance use disorder and chronic cough. The company also holds a 20% stake in Neurosterix LLC, which is developing allosteric modulators for various neurological disorders.
Addex Therapeutics 宣布，其 2024 年年度股东大会上，股东批准了所有董事会提案，代表了 33.79% 的流通资本。关键的批准包括 2023 年年度报告、基本报表和薪酬报告。董事会成员，包括主席文森特·劳顿博士，均获得连任，BDO SA 被重新任命为审计师。股东们还批准了《公司章程》的修订，包括资本带和有条件股份资本的增加。这些变更符合修订后的公司法，并解决了与股东、股东大会、董事会职责及薪酬限制相关的问题。该公司的首个药物候选 ADX71149 最近完成了针对癫痫治疗的第二阶段研究。Addex 正在推进多个药物开发项目，包括用于帕金森病相关运动障碍的 dipraglurant，以及与 Indivior 在 GABAb PAm 上的合作，针对物质使用障碍和慢性咳嗽。该公司还持有 Neurosterix LLC 的 20% 股份，该公司正在开发用于多种神经系统疾病的别构调节剂。
Addex Therapeutics 宣布，其 2024 年年度股东大会上，股东批准了所有董事会提案，代表了 33.79% 的流通资本。关键的批准包括 2023 年年度报告、基本报表和薪酬报告。董事会成员，包括主席文森特·劳顿博士，均获得连任，BDO SA 被重新任命为审计师。股东们还批准了《公司章程》的修订，包括资本带和有条件股份资本的增加。这些变更符合修订后的公司法，并解决了与股东、股东大会、董事会职责及薪酬限制相关的问题。该公司的首个药物候选 ADX71149 最近完成了针对癫痫治疗的第二阶段研究。Addex 正在推进多个药物开发项目，包括用于帕金森病相关运动障碍的 dipraglurant，以及与 Indivior 在 GABAb PAm 上的合作，针对物质使用障碍和慢性咳嗽。该公司还持有 Neurosterix LLC 的 20% 股份，该公司正在开发用于多种神经系统疾病的别构调节剂。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

独立文件2  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    相关股票 相关股票
    代码 迷你走势 最新价
    Sana Biotechnology
    SANA
    -- 4.300
    Vir Biotechnology
    VIR
    -- 12.480
    Silo Pharma
    SILO
    -- 1.710
    Compass Therapeutics
    CMPX
    -- 1.860
    NLS Pharmaceutics
    NLSP
    -- 2.4100

    解锁榜首股票

    热门讨论
    特朗普2.0时代倒计时！全球股市的下一个风口？
    特朗普即将重返政治舞台！特朗普提出的“美国优先”关税政策、加密货币政策以及对科技行业的影响，已成为市场关注的焦点。在此背景下，crypto、Tesla、AI板块的未来走势值得关注。 🎙️️讨论： 1. 加密货币政策能否利好crypto？ 2. 关税政策能否利好中概等海外资产？ 展开
    询问策略师 - 川普的首日
    查看更多